Platform production processes simplify process development and make it easier to scale up effectively. Similarly, a platform analytical testing strategy reduces the time for assay development. We describe key considerations when building such an integrated platform for viral vectors, and propose near-term and future-state solutions.
In this webinar, you will learn:
- Suspension-based upstream viral vector platforms
- Analytical testing strategies for viral vector production
- Final filtration and cost-modeling for viral vectors
Speaker
David Loong, Ph.D.
{hcompany}
Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy
David Loong is our senior consultant, novel modalities APAC, bioprocessing strategy. Previously, David held roles as a senior scientist in biotech startups encompassing cell & gene therapy process development services, mAb discovery, and preclinical development. He has an extensive track record providing contract research services as a senior research scientist at AMRI Global, and as a product custodian for API GMP manufacturing at GSK. He holds a Ph.D. in synthetic organic chemistry from the Australian National University and a BTech(Hons) from Massey University (NZ) specializing in chemistry and process engineering.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
Duración:1h
Idioma:English
Sesión 1:presentado April 20, 2021
Para seguir leyendo, inicie sesión o cree una cuenta.
¿No tiene una cuenta?